The Severity of Newly Diagnosed Asthma Patients and the Result of Initial 12 Weeks Treatment in China (INITIAL)
The Severity of Newly Diagnosed Asthma Patients and the Result of Initial 12 Weeks Treatment in China.
Sponsor: AstraZeneca
Listed as NCT02143739, this observational or N/A phase trial focuses on Asthma and remains completed. Sponsored by AstraZeneca, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Oct 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Oct 2017 [monthly]
Completed NA
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baotou, China , Beijing, China , Changsha, China , Changshu, China , Chengdu, China , Chongqing, China , Dalian, China , Daping, China , Fuzhou, China , Guangyuan, China and 20 more locations